Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan Purchases 55,256 Shares

Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan acquired 55,256 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was purchased at an average price of $17.18 per share, with a total value of $949,298.08. Following the acquisition, the director now owns 42,328,717 shares of the company’s stock, valued at $727,207,358.06. This represents a 0.13 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Pulse Biosciences Trading Down 7.3 %

PLSE stock opened at $17.83 on Thursday. The firm has a 50 day moving average price of $17.81 and a 200-day moving average price of $16.55. Pulse Biosciences, Inc. has a 52-week low of $6.59 and a 52-week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter last year, the firm posted ($0.19) earnings per share.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research note on Thursday, December 12th.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds have recently bought and sold shares of PLSE. Price T Rowe Associates Inc. MD bought a new stake in Pulse Biosciences during the 1st quarter valued at about $88,000. Quest Partners LLC bought a new stake in shares of Pulse Biosciences during the second quarter valued at approximately $91,000. Cetera Advisors LLC purchased a new position in Pulse Biosciences in the 1st quarter worth approximately $109,000. Rhumbline Advisers lifted its position in Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after acquiring an additional 1,608 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new stake in Pulse Biosciences during the 3rd quarter valued at $378,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.